Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Allena Pharmaceuticals, Inc.ALNA · Entity 130904 | Director | June 03, 2021 | June 04, 2021 |
| INOVIO PHARMACEUTICALS, INC.INO · Entity 6589 | Director | May 20, 2026 | May 21, 2026 |
| PUMA BIOTECHNOLOGY, INC.PBYI · Entity 5478 | Director | June 15, 2021 | June 18, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Allena Pharmaceuticals, Inc.
Report date June 03, 2021 · Filed June 04, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.14 · Expires 2031-06-02 | Direct | 37,000 |
Reported balance
After 2021-06-03 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-06-03 · Grant · Acquired 37,000 · Balance 37,000 F1: Stock option shall vest in full (i.e., in single installment) upon the earlier to occur of the first anniversary of the date of grant or the date of the next annual meeting of stockholders. |
Filing footnotes · ownership attribution and instrument terms
F1: Stock option shall vest in full (i.e., in single installment) upon the earlier to occur of the first anniversary of the date of grant or the date of the next annual meeting of stockholders.
INOVIO PHARMACEUTICALS, INC.
Report date May 20, 2026 · Filed May 21, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $1.23 · Expires 2036-05-20 | Direct | 41,800 |
Reported balance
After 2026-05-20 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-05-20 · Grant · Acquired 41,800 · Balance 41,800 F1: This grant was made under the 2023 Omnibus Incentive Plan pursuant to the issuer's non-employee director compensation policy. F2: Options to vest 100% on May 20, 2027. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 34,200 |
Reported balance
After 2026-05-20 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-05-20 · Grant · Acquired 34,200 · Balance 34,200 F3: Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units will vest 100% on May 20, 2027. F1: This grant was made under the 2023 Omnibus Incentive Plan pursuant to the issuer's non-employee director compensation policy. |
Filing footnotes · ownership attribution and instrument terms
F1: This grant was made under the 2023 Omnibus Incentive Plan pursuant to the issuer's non-employee director compensation policy.
F2: Options to vest 100% on May 20, 2027.
F3: Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units will vest 100% on May 20, 2027.
PUMA BIOTECHNOLOGY, INC.
Report date June 15, 2021 · Filed June 18, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| COMMON STOCKSEC Table I · non-derivative | Direct | 40,732 |
Reported balance
After 2021-06-15 transaction · row 1
1 source rowRow 1 · 2021-06-15 · Grant · Acquired 27,858 · Balance 40,732 F1: Represents Restricted Stock Units which vest in full on the earlier of the one-year anniversary of the date of grant and the date of the annual shareholder meeting following the date of grant, subject to the Reporting Person's continued service with the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents Restricted Stock Units which vest in full on the earlier of the one-year anniversary of the date of grant and the date of the annual shareholder meeting following the date of grant, subject to the Reporting Person's continued service with the Issuer.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 20, 2026 Filed May 21, 2026 20:11 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | GrantRestricted Stock Unit · Derivative | 34,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001771423-26-000001 · wk-form4_1779394312.xml · derivative · entry 2 Miller Ann Calby · CIK 0001771423 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,200 Underlying: Common Stock · 34,200 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units will vest 100% on May 20, 2027. F1 · shares: This grant was made under the 2023 Omnibus Incentive Plan pursuant to the issuer's non-employee director compensation policy. F3 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units will vest 100% on May 20, 2027. F3 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units will vest 100% on May 20, 2027. Read SEC document |
| May 20, 2026 Filed May 21, 2026 20:11 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | GrantCommon Stock Options · Derivative | 41,800 | $0.00 Strike: $1.23 | $0.00 |
DisclosureSEC source: 0001771423-26-000001 · wk-form4_1779394312.xml · derivative · entry 1 Miller Ann Calby · CIK 0001771423 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,800 Underlying: Common Stock · 41,800 shares Expires 2036-05-20 F1 · shares: This grant was made under the 2023 Omnibus Incentive Plan pursuant to the issuer's non-employee director compensation policy. F2 · derivative.exercise_date: Options to vest 100% on May 20, 2027. Read SEC document |
| May 21, 2025 Filed May 21, 2025 20:58 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionRestricted Stock Unit · Derivative | 2,167 | $0.00 | $0.00 |
DisclosureSEC source: 0001055726-25-000039 · wk-form4_1747861099.xml · derivative · entry 2 Miller Ann Calby · CIK 0001771423 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,167 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units vested 100% on May 21, 2025. F1 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units vested 100% on May 21, 2025. F1 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units vested 100% on May 21, 2025. Read SEC document |
| May 21, 2025 Filed May 21, 2025 20:58 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionCommon Stock | 2,167 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001055726-25-000039 · wk-form4_1747861099.xml · nonDerivative · entry 1 Miller Ann Calby · CIK 0001771423 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,877 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units vested 100% on May 21, 2025. Read SEC document |
| May 21, 2024 Filed May 22, 2024 20:51 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | GrantRestricted Stock Unit · Derivative | 2,167 | $0.00 | $0.00 |
DisclosureSEC source: 0001055726-24-000039 · wk-form4_1716411064.xml · derivative · entry 2 Miller Ann Calby · CIK 0001771423 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,167 Underlying: Common Stock · 2,167 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units will vest 100% on May 21, 2025. F1 · shares: This grant was made under the 2023 Omnibus Incentive Plan pursuant to the issuer's non-employee director compensation policy. F3 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units will vest 100% on May 21, 2025. F3 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units will vest 100% on May 21, 2025. Read SEC document |
| May 21, 2024 Filed May 22, 2024 20:51 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | GrantCommon Stock Options · Derivative | 2,917 | $0.00 Strike: $10.99 | $0.00 |
DisclosureSEC source: 0001055726-24-000039 · wk-form4_1716411064.xml · derivative · entry 1 Miller Ann Calby · CIK 0001771423 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,917 Underlying: Common Stock · 2,917 shares Expires 2034-05-21 F1 · shares: This grant was made under the 2023 Omnibus Incentive Plan pursuant to the issuer's non-employee director compensation policy. F2 · derivative.exercise_date: Options to vest 100% on May 21, 2025. Read SEC document |
| May 15, 2024 Filed May 16, 2024 21:13 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionRestricted Stock Unit · Derivative | 2,166 | $0.00 | $0.00 |
DisclosureSEC source: 0001055726-24-000034 · wk-form4_1715893968.xml · derivative · entry 2 Miller Ann Calby · CIK 0001771423 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,166 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units vested 100% on May 15, 2024. F2 · shares: Gives effect to a 1-for-12 reverse stock split effected by the Issuer on January 24, 2024. F1 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units vested 100% on May 15, 2024. F1 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units vested 100% on May 15, 2024. F2 · derivative.underlying_shares: Gives effect to a 1-for-12 reverse stock split effected by the Issuer on January 24, 2024. Read SEC document |
| May 15, 2024 Filed May 16, 2024 21:13 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionCommon Stock | 2,166 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001055726-24-000034 · wk-form4_1715893968.xml · nonDerivative · entry 1 Miller Ann Calby · CIK 0001771423 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,710 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units vested 100% on May 15, 2024. F2 · balance_after: Gives effect to a 1-for-12 reverse stock split effected by the Issuer on January 24, 2024. Read SEC document |
| May 16, 2023 Filed May 16, 2023 20:50 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionRestricted Stock Unit · Derivative | 19,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001055726-23-000034 · wk-form4_1684270239.xml · derivative · entry 2 Miller Ann Calby · CIK 0001771423 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 19,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units vested 100% on May 16, 2023. F1 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units vested 100% on May 16, 2023. F1 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units vested 100% on May 16, 2023. Read SEC document |
| May 16, 2023 Filed May 16, 2023 20:50 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionCommon Stock | 19,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001055726-23-000034 · wk-form4_1684270239.xml · nonDerivative · entry 1 Miller Ann Calby · CIK 0001771423 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 66,534 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units vested 100% on May 16, 2023. Read SEC document |
| May 15, 2023 Filed May 16, 2023 20:50 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | GrantRestricted Stock Unit · Derivative | 26,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001055726-23-000034 · wk-form4_1684270239.xml · derivative · entry 4 Miller Ann Calby · CIK 0001771423 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,000 Underlying: Common Stock · 26,000 shares Expires not disclosed F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units will vest 100% on May 15, 2024. F2 · shares: This grant was made under the 2016 Omnibus Incentive Plan pursuant to the issuer's non-employee director compensation policy. F4 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units will vest 100% on May 15, 2024. F4 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units will vest 100% on May 15, 2024. Read SEC document |
| May 15, 2023 Filed May 16, 2023 20:50 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | GrantCommon Stock Options · Derivative | 35,000 | $0.00 Strike: $0.77 | $0.00 |
DisclosureSEC source: 0001055726-23-000034 · wk-form4_1684270239.xml · derivative · entry 3 Miller Ann Calby · CIK 0001771423 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2033-05-15 F2 · shares: This grant was made under the 2016 Omnibus Incentive Plan pursuant to the issuer's non-employee director compensation policy. F3 · derivative.exercise_date: Options to vest 100% on May 15, 2024. Read SEC document |
| May 16, 2022 Filed May 17, 2022 20:24 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | GrantCommon Stock Options · Derivative | 28,000 | $0.00 Strike: $1.89 | $0.00 |
DisclosureSEC source: 0001055726-22-000037 · wf-form4_165281902186670.xml · derivative · entry 4 Miller Ann Calby · CIK 0001771423 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,000 Underlying: Common Stock · 28,000 shares Expires 2032-05-16 F3 · shares: This grant was made pursuant to the issuer's non-employee director compensation policy. F4 · derivative.exercise_date: Options to vest 100% on May 16, 2023. Read SEC document |
| May 16, 2022 Filed May 17, 2022 20:24 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | GrantRestricted Stock Unit · Derivative | 19,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001055726-22-000037 · wf-form4_165281902186670.xml · derivative · entry 3 Miller Ann Calby · CIK 0001771423 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,000 Underlying: Common Stock · 19,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units will vest 100% on May 16, 2023. F3 · shares: This grant was made pursuant to the issuer's non-employee director compensation policy. F2 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units will vest 100% on May 16, 2023. F2 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units will vest 100% on May 16, 2023. Read SEC document |
| May 13, 2022 Filed May 17, 2022 20:24 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionRestricted Stock Unit · Derivative | 18,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001055726-22-000037 · wf-form4_165281902186670.xml · derivative · entry 2 Miller Ann Calby · CIK 0001771423 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 18,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units vested 100% on May 13, 2022. F1 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units vested 100% on May 13, 2022. F1 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units vested 100% on May 13, 2022. Read SEC document |
| May 13, 2022 Filed May 17, 2022 20:24 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionCommon Stock | 18,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001055726-22-000037 · wf-form4_165281902186670.xml · nonDerivative · entry 1 Miller Ann Calby · CIK 0001771423 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,534 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units vested 100% on May 13, 2022. Read SEC document |
| March 21, 2022 Filed Mar 22, 2022 20:15 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionRestricted Stock Unit · Derivative | 4,273 | $0.00 | $0.00 |
DisclosureSEC source: 0001055726-22-000026 · wf-form4_164798010210819.xml · derivative · entry 2 Miller Ann Calby · CIK 0001771423 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,273 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 12,821 restricted stock units is as follows: 4,274 shares vested on March 21, 2020; 4,274 shares vested on March 21, 2021; 4,273 shares vested on March 21, 2022. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F1 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 12,821 restricted stock units is as follows: 4,274 shares vested on March 21, 2020; 4,274 shares vested on March 21, 2021; 4,273 shares vested on March 21, 2022. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F1 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 12,821 restricted stock units is as follows: 4,274 shares vested on March 21, 2020; 4,274 shares vested on March 21, 2021; 4,273 shares vested on March 21, 2022. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. Read SEC document |
| March 21, 2022 Filed Mar 22, 2022 20:15 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionCommon Stock | 4,273 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001055726-22-000026 · wf-form4_164798010210819.xml · nonDerivative · entry 1 Miller Ann Calby · CIK 0001771423 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,534 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 12,821 restricted stock units is as follows: 4,274 shares vested on March 21, 2020; 4,274 shares vested on March 21, 2021; 4,273 shares vested on March 21, 2022. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. Read SEC document |
| June 15, 2021 Filed Jun 18, 2021 00:50 UTC | PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 | GrantCOMMON STOCK | 27,858 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-041787 · doc4.xml · nonDerivative · entry 1 Miller Ann Calby · CIK 0001771423 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,732 F1 · shares: Represents Restricted Stock Units which vest in full on the earlier of the one-year anniversary of the date of grant and the date of the annual shareholder meeting following the date of grant, subject to the Reporting Person's continued service with the Issuer. Read SEC document |
| June 10, 2021 Filed Jun 11, 2021 20:59 UTC | PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 | SaleCOMMON STOCK | 12,874 | $11.43 | $147,156.26 |
DisclosureSEC source: 0001209191-21-039897 · doc4.xml · nonDerivative · entry 1 Miller Ann Calby · CIK 0001771423 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,874 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.36 to $11.52, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 03, 2021 Filed Jun 4, 2021 16:00 UTC | Allena Pharmaceuticals, Inc. ALNA · Entity 130904 | GrantStock Option (Right to Buy) · Derivative | 37,000 | $0.00 Strike: $1.14 | $0.00 |
DisclosureSEC source: 0001209191-21-038169 · doc4.xml · derivative · entry 1 Miller Ann Calby · CIK 0001771423 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,000 Underlying: Common Stock · 37,000 shares Expires 2031-06-02 F1 · derivative.exercise_date: Stock option shall vest in full (i.e., in single installment) upon the earlier to occur of the first anniversary of the date of grant or the date of the next annual meeting of stockholders. Read SEC document |
| May 14, 2021 Filed May 17, 2021 20:30 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionRestricted Stock Unit · Derivative | 8,700 | $0.00 | $0.00 |
DisclosureSEC source: 0001055726-21-000048 · wf-form4_162128338799111.xml · derivative · entry 4 Miller Ann Calby · CIK 0001771423 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,700 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units vested 100% on May 14, 2021. F1 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units vested 100% on May 14, 2021. F1 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units vested 100% on May 14, 2021. Read SEC document |
| May 14, 2021 Filed May 17, 2021 20:30 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionCommon Stock | 8,700 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001055726-21-000048 · wf-form4_162128338799111.xml · nonDerivative · entry 1 Miller Ann Calby · CIK 0001771423 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,261 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units vested 100% on May 14, 2021. Read SEC document |
| May 13, 2021 Filed May 17, 2021 20:30 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | GrantRestricted Stock Unit · Derivative | 18,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001055726-21-000048 · wf-form4_162128338799111.xml · derivative · entry 3 Miller Ann Calby · CIK 0001771423 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,000 Underlying: Common Stock · 18,000 shares Expires not disclosed F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units will vest 100% on May 13, 2022. F2 · shares: This grant was made pursuant to the issuer's non-employee director compensation policy. F4 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units will vest 100% on May 13, 2022. F4 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units will vest 100% on May 13, 2022. Read SEC document |
| May 13, 2021 Filed May 17, 2021 20:30 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | GrantCommon Stock Options · Derivative | 27,000 | $0.00 Strike: $6.23 | $0.00 |
DisclosureSEC source: 0001055726-21-000048 · wf-form4_162128338799111.xml · derivative · entry 2 Miller Ann Calby · CIK 0001771423 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,000 Underlying: Common Stock · 27,000 shares Expires 2031-05-13 F2 · shares: This grant was made pursuant to the issuer's non-employee director compensation policy. F3 · derivative.exercise_date: Options to vest 100% on May 13, 2022. Read SEC document |
| March 21, 2021 Filed Mar 23, 2021 20:43 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionRestricted Stock Unit · Derivative | 4,274 | $0.00 | $0.00 |
DisclosureSEC source: 0001055726-21-000030 · wf-form4_161653218079462.xml · derivative · entry 2 Miller Ann Calby · CIK 0001771423 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,273 Underlying: Common Stock · 4,274 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 12,821 restricted stock units is as follows: 4,274 shares vested on March 21, 2020; 4,274 shares vested on March 21, 2021; 4,273 shares will vest on March 21, 2022. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F1 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 12,821 restricted stock units is as follows: 4,274 shares vested on March 21, 2020; 4,274 shares vested on March 21, 2021; 4,273 shares will vest on March 21, 2022. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F1 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 12,821 restricted stock units is as follows: 4,274 shares vested on March 21, 2020; 4,274 shares vested on March 21, 2021; 4,273 shares will vest on March 21, 2022. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. Read SEC document |
| March 21, 2021 Filed Mar 23, 2021 20:43 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionCommon Stock | 4,274 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001055726-21-000030 · wf-form4_161653218079462.xml · nonDerivative · entry 1 Miller Ann Calby · CIK 0001771423 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,561 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 12,821 restricted stock units is as follows: 4,274 shares vested on March 21, 2020; 4,274 shares vested on March 21, 2021; 4,273 shares will vest on March 21, 2022. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. Read SEC document |
| October 05, 2020 Filed Oct 6, 2020 18:02 UTC | Allena Pharmaceuticals, Inc. ALNA · Entity 130904 | GrantStock Option (Right to Buy) · Derivative | 28,000 | $0.00 Strike: $1.69 | $0.00 |
DisclosureSEC source: 0000899243-20-027641 · doc4.xml · derivative · entry 1 Miller Ann Calby · CIK 0001771423 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,000 Underlying: Common Stock · 28,000 shares Expires 2030-10-05 F1 · derivative.exercise_date: Stock option shall vest ratably over three years in annual installments beginning on October 5, 2020. Read SEC document |
| June 09, 2020 Filed Jun 10, 2020 21:14 UTC | PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 | GrantCOMMON STOCK | 25,748 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-035603 · doc4.xml · nonDerivative · entry 1 Miller Ann Calby · CIK 0001771423 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,748 F1 · shares: Represents Restricted Stock Units which vest in full on the earlier of the one-year anniversary of the date of grant and the date of the annual shareholder meeting following the date of grant, subject to the Reporting Person's continued service with the Issuer. Read SEC document |
| May 14, 2020 Filed May 15, 2020 20:09 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | GrantRestricted Stock Unit · Derivative | 8,700 | $0.00 | $0.00 |
DisclosureSEC source: 0001055726-20-000038 · wf-form4_158957332323996.xml · derivative · entry 2 Miller Ann Calby · CIK 0001771423 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,700 Underlying: Common Stock · 8,700 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units will vest 100% on May 14, 2021. F1 · shares: This grant was made pursuant to the issuer's non-employee director compensation policy. F3 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units will vest 100% on May 14, 2021. F3 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units will vest 100% on May 14, 2021. Read SEC document |
| May 14, 2020 Filed May 15, 2020 20:09 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | GrantCommon Stock Options · Derivative | 13,300 | $0.00 Strike: $13.65 | $0.00 |
DisclosureSEC source: 0001055726-20-000038 · wf-form4_158957332323996.xml · derivative · entry 1 Miller Ann Calby · CIK 0001771423 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,300 Underlying: Common Stock · 13,300 shares Expires 2030-05-14 F1 · shares: This grant was made pursuant to the issuer's non-employee director compensation policy. F2 · derivative.exercise_date: Options to vest 100% on May 14, 2021. Read SEC document |
| May 08, 2020 Filed May 8, 2020 22:18 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionRestricted Stock Unit · Derivative | 8,013 | $0.00 | $0.00 |
DisclosureSEC source: 0001055726-20-000025 · wf-form4_158897629126919.xml · derivative · entry 2 Miller Ann Calby · CIK 0001771423 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,013 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units vested 100% on May 8, 2020. F1 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units vested 100% on May 8, 2020. F1 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units vested 100% on May 8, 2020. Read SEC document |
| May 08, 2020 Filed May 8, 2020 22:18 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionCommon Stock | 8,013 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001055726-20-000025 · wf-form4_158897629126919.xml · nonDerivative · entry 1 Miller Ann Calby · CIK 0001771423 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,287 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units vested 100% on May 8, 2020. Read SEC document |
| March 21, 2020 Filed Mar 23, 2020 20:54 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionRestricted Stock Unit · Derivative | 4,274 | $0.00 | $0.00 |
DisclosureSEC source: 0001055726-20-000018 · wf-form4_158499686758704.xml · derivative · entry 2 Miller Ann Calby · CIK 0001771423 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,547 Underlying: Common Stock · 4,274 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 12,821 restricted stock units is as follows: 4,274 shares vested on March 21, 2020; 4,274 shares will vest on March 21, 2021; 4,273 shares will vest on March 21, 2022. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 12,821 restricted stock units is as follows: 4,274 shares vested on March 21, 2020; 4,274 shares will vest on March 21, 2021; 4,273 shares will vest on March 21, 2022. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F1 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 12,821 restricted stock units is as follows: 4,274 shares vested on March 21, 2020; 4,274 shares will vest on March 21, 2021; 4,273 shares will vest on March 21, 2022. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F1 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 12,821 restricted stock units is as follows: 4,274 shares vested on March 21, 2020; 4,274 shares will vest on March 21, 2021; 4,273 shares will vest on March 21, 2022. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. Read SEC document |
| March 21, 2020 Filed Mar 23, 2020 20:54 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionCommon Stock | 4,274 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001055726-20-000018 · wf-form4_158499686758704.xml · nonDerivative · entry 1 Miller Ann Calby · CIK 0001771423 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,274 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 12,821 restricted stock units is as follows: 4,274 shares vested on March 21, 2020; 4,274 shares will vest on March 21, 2021; 4,273 shares will vest on March 21, 2022. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. Read SEC document |
| November 12, 2019 Filed Nov 13, 2019 23:02 UTC | PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 | GrantStock Option (Right to Buy) · Derivative | 125,306 | $0.00 Strike: $8.45 | $0.00 |
DisclosureSEC source: 0001209191-19-056460 · doc4.xml · derivative · entry 1 Miller Ann Calby · CIK 0001771423 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,306 Underlying: Common Stock · 125,306 shares Expires 2029-11-11 F1 · derivative.exercise_date: The vesting commencement date ("Vesting Commencement Date") of the option is November 12, 2019. The option vests (i) with respect to one-third (1/3) of the shares underlying the option on the first anniversary of the Vesting Commencement Date and (ii) with respect to 1/36th of the shares underlying the option, on each monthly anniversary of the Vesting Commencement Date thereafter, subject to the Reporting Person's continued service with the Issuer through the applicable vesting date. Read SEC document |
| May 08, 2019 Filed May 9, 2019 22:07 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | GrantRestricted Stock Unit · Derivative | 8,013 | $0.00 | $0.00 |
DisclosureSEC source: 0001055726-19-000035 · wf-form4_155743962422476.xml · derivative · entry 2 Miller Ann Calby · CIK 0001771423 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,013 Underlying: Common Stock · 8,013 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units will vest 100% on May 8, 2020. F1 · shares: This grant was made pursuant to the issuer's non-employee director compensation policy. F3 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units will vest 100% on May 8, 2020. F3 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units will vest 100% on May 8, 2020. Read SEC document |
| May 08, 2019 Filed May 9, 2019 22:07 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | GrantCommon Stock Options · Derivative | 12,500 | $0.00 Strike: $3.90 | $0.00 |
DisclosureSEC source: 0001055726-19-000035 · wf-form4_155743962422476.xml · derivative · entry 1 Miller Ann Calby · CIK 0001771423 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires 2029-05-08 F1 · shares: This grant was made pursuant to the issuer's non-employee director compensation policy. F2 · derivative.exercise_date: Options to vest with respect to 100% of the shares on May 8, 2020. Read SEC document |
| March 21, 2019 Filed Mar 25, 2019 20:32 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | GrantCommon Stock Option · Derivative | 20,000 | $0.00 Strike: $3.72 | $0.00 |
DisclosureSEC source: 0001055726-19-000023 · wf-form4_155354590590249.xml · derivative · entry 2 Miller Ann Calby · CIK 0001771423 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2029-03-21 F2 · shares: This grant was made pursuant to the issuer's non-employee director compensation policy. F3 · derivative.exercise_date: The vesting schedule for the 20,000 options is as follows: 5,000 shares vested on March 21, 2019; 5,000 shares will vest on March 21, 2020; 5,000 shares will vest on March 21, 2021; 5,000 shares will vest on March 21, 2022. Read SEC document |
| March 21, 2019 Filed Mar 25, 2019 20:32 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | GrantRestricted Stock Unit · Derivative | 12,821 | $0.00 | $0.00 |
DisclosureSEC source: 0001055726-19-000023 · wf-form4_155354590590249.xml · derivative · entry 1 Miller Ann Calby · CIK 0001771423 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,821 Underlying: Common Stock · 12,821 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 12,821 restricted stock units is as follows: 4,274 shares will vest on March 21, 2020; 4,274 shares will vest on March 21, 2021; 4,273 shares will vest on March 21, 2022. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F2 · shares: This grant was made pursuant to the issuer's non-employee director compensation policy. F1 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 12,821 restricted stock units is as follows: 4,274 shares will vest on March 21, 2020; 4,274 shares will vest on March 21, 2021; 4,273 shares will vest on March 21, 2022. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F1 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 12,821 restricted stock units is as follows: 4,274 shares will vest on March 21, 2020; 4,274 shares will vest on March 21, 2021; 4,273 shares will vest on March 21, 2022. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.